Zhejiang Peptites Biotech Co., Ltd. (abbreviated as ZPC below), founded in 2015, is driven by the mission of "humans are healthier and more beautiful due to peptides", and continues to strive for a better way of life for humanity. ZPC has rapidly grown into a leader in the field of peptides. As a national high-tech enterprise and a national-level specialized, refined, characteristic, and innovative “small giant enterprise”, the company has more than 900 employees and a large R&D team, supported by 87 patents.
Backed by a portfolio of independently developed core technologies, ZPC has successfully launched over 60 high-quality, high-value-added peptide active pharmaceutical ingredients (APIs), including Leuprolide Acetate, Liraglutide, Semaglutide, Tirzepatide, Cagrilintide, Retatrutide, and Linaclotide. In addition, it provides more than 40 cosmetic peptide raw materials, covering multiple application fields such as anti-wrinkle, anti-aging, skin repair, and skin brightening. The company’s quality management system is certified for FDA cGMP compliance and also meets the GMP standards of the EU, WHO and ICH Q7. Furthermore, its integrated management system holds EcoVadis medal, HALAL and RSPO certifications.
The annual production capacity of ZPC is 8,000 kg of peptide powder and 2,000 tons of peptide solution, and the company is improving production efficiency further to meet the growing demand for high-quality APIs in both domestic and overseas markets. The company also offers CMO and CDMO services that provide one-stop solutions from R&D to production for global customers, helping them accelerate the process of launching new drugs to the market. In the future, ZPC will continue to deepen its commitment to the peptide API field, making even greater contributions to advancing global human health.